Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Current Liabilities: 2016-2024

Historic Total Current Liabilities for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $90.7 million.

  • Tg Therapeutics' Total Current Liabilities rose 25.33% to $156.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.8 million, marking a year-over-year increase of 25.33%. This contributed to the annual value of $90.7 million for FY2024, which is 68.80% up from last year.
  • As of FY2024, Tg Therapeutics' Total Current Liabilities stood at $90.7 million, which was up 68.80% from $53.7 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Total Current Liabilities registered a high of $90.7 million during FY2024, and its lowest value of $53.2 million during FY2022.
  • For the 3-year period, Tg Therapeutics' Total Current Liabilities averaged around $65.9 million, with its median value being $53.7 million (2023).
  • Per our database at Business Quant, Tg Therapeutics' Total Current Liabilities decreased by 25.32% in 2021 and then surged by 68.80% in 2024.
  • Tg Therapeutics' Total Current Liabilities (Yearly) stood at $87.6 million in 2020, then decreased by 25.32% to $65.4 million in 2021, then fell by 18.63% to $53.2 million in 2022, then climbed by 0.98% to $53.7 million in 2023, then skyrocketed by 68.80% to $90.7 million in 2024.